Is HIMS stock a hidden gem for 2030? 📈

Ajouté : 2026-05-25

[00:00:00]It is the most conservative, honest scenario. Now, the base case, a partial re-rating, and we do hit our $6.5 billion target, the market potentially re-rates at 40 times earnings, recognizing it is a subscription-based, not a pharmacy. At a 2030 EPS of $2, the stock price will be $80, plus 196 from today. This requires management to execute on what they have already guided, and the market to give them a slightly higher multiple. Now, the bull scenario, the full re-rating inside of this, if they do get to that $7.8 billion target in 2030, a full rate re-rating to subscription tech multiple at 55 times, the market then reclassifies Hims as healthcare infrastructure.